Ilyang Pharmaceutical Co.,Ltd
KSC: 007575.KS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Korea Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Dong-Yeon Kim
- Employees
- 637
- Headquarters
- Yongin, South Korea
- IPO year
- 2005
- Market cap
- ₩184.6B
- Website
- https://www.ilyang.co.kr
Loading 007575…
Loading profile data…Frequently asked questions about 007575
What does Ilyang Pharmaceutical Co.,Ltd (007575.KS) do?
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neu...
Where does 007575.KS trade?
Ilyang Pharmaceutical Co.,Ltd (007575.KS) trades on the Korea Exchange.
What sector is 007575.KS in?
Ilyang Pharmaceutical Co.,Ltd (007575.KS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Ilyang Pharmaceutical Co.,Ltd?
Dong-Yeon Kim is the chief executive officer of Ilyang Pharmaceutical Co.,Ltd (007575.KS).
Where is Ilyang Pharmaceutical Co.,Ltd headquartered?
Ilyang Pharmaceutical Co.,Ltd is headquartered in South Korea.
Does 007575.KS pay a dividend?
Yes — Ilyang Pharmaceutical Co.,Ltd (007575.KS) paid a trailing twelve-month dividend of KRW 180.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 007575.KS go public?
Ilyang Pharmaceutical Co.,Ltd (007575.KS) completed its initial public offering in 2005.